We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $2.19B
1-Year Est. Return 374.99%
This Fund
S&P 500
This Quarter Est. Return
+8.25%
1 Year Est. Return
+374.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.7B
AUM Growth
+$337M
Cap. Flow
+$308M
Cap. Flow %
18.12%
Top 10 Hldgs %
39.64%
Holding
351
New
78
Increased
102
Reduced
60
Closed
41

Top Buys

Rank Stock Value
1
BEAM icon
Beam Therapeutics
BEAM
+$40.1M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$37.1M
3
DNLI icon
Denali Therapeutics
DNLI
+$36.2M
4
INSP icon
Inspire Medical Systems
INSP
+$27.3M
5
VIR icon
Vir Biotechnology
VIR
+$21.9M

Top Sells

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$39.4M
2
RAPT
RAPT Therapeutics
RAPT
+$17.3M
3
CDTX
Cidara Therapeutics
CDTX
+$13.2M
4
FULC icon
Fulcrum Therapeutics
FULC
+$10.4M
5
ABUS icon
Arbutus Biopharma
ABUS
+$9.98M

Sector Composition

Rank Sector Weight
1 Healthcare 88.42%
2 Miscellaneous 9.68%
3 Financials 1.51%
4 Technology 0.08%
5 Industrials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELAN icon
201
Elanco Animal Health
ELAN
$12B
$479K 0.03%
20,000
– –
NVO
202
CALL
Novo Nordisk
NVO
$202B
$478K 0.03%
+13,000
New +$616K
PHAT icon
203
Phathom Pharmaceuticals
PHAT
$743M
$477K 0.03%
42,900
– –
MDGL icon
204
Madrigal Pharmaceuticals
MDGL
$12.3B
$469K 0.03%
895
– –
PYPD icon
205
PolyPid
PYPD
$103M
$455K 0.03%
103,950
– –
BABA icon
206
Alibaba
BABA
$296B
$449K 0.03%
3,578
– –
CORZ icon
207
Core Scientific
CORZ
$5.31B
$449K 0.03%
30,000
– –
WHWK
208
Whitehawk Therapeutics
WHWK
$263M
$443K 0.03%
128,503
+50,910
+66% +$159K
NTRA icon
209
Natera
NTRA
$47B
$429K 0.03%
2,147
– –
VTGN icon
210
VistaGen Therapeutics
VTGN
$11.2M
$429K 0.03%
751,141
+127,566
+20% +$77.5K
TXMD icon
211
TherapeuticsMD
TXMD
$25.7M
$423K 0.02%
209,210
– –
RARE icon
212
CALL
Ultragenyx Pharmaceutical
RARE
$2.52B
$419K 0.02%
20,000
+10,000
+100% +$225K
SNDX icon
213
Syndax Pharmaceuticals
SNDX
$1.74B
$409K 0.02%
17,500
+5,500
+46% +$120K
TECX
214
Tectonic Therapeutic
TECX
$696M
$402K 0.02%
13,001
-17,006
-57% -$419K
TRDA icon
215
Entrada Therapeutics
TRDA
$273M
$385K 0.02%
+30,500
New +$350K
BHVN icon
216
Biohaven
BHVN
$2.33B
$379K 0.02%
44,777
+10,500
+31% +$115K
MRK icon
217
Merck
MRK
$366B
$378K 0.02%
3,140
-6,500
-67% -$750K
VSTM icon
218
Verastem
VSTM
$654M
$377K 0.02%
+71,100
New +$438K
MLTX icon
219
CALL
MoonLake Immunotherapeutics
MLTX
$1.28B
$373K 0.02%
+20,000
New +$331K
RGNX icon
220
Regenxbio
RGNX
$638M
$372K 0.02%
44,416
-100,432
-69% -$1.06M
ACET icon
221
Adicet Bio
ACET
$84.8M
$367K 0.02%
53,827
-74,819
-58% -$560K
LEGN icon
222
Legend Biotech
LEGN
$3.87B
$362K 0.02%
+20,000
New +$381K
SRZN icon
223
Surrozen
SRZN
$264M
$350K 0.02%
+12,000
New +$288K
ZNTL icon
224
Zentalis Pharmaceuticals
ZNTL
$360M
$338K 0.02%
144,636
+64,636
+81% +$167K
BCYC
225
Bicycle Therapeutics
BCYC
$294M
$331K 0.02%
+71,298
New +$407K
7 8
9
10 11

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $2.19B AUM 50.16% 1-Year Est. Return
RCAG
Rehmann Capital Advisory Group Lansing, Michigan $2.18B AUM 23.73% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $2.19B AUM 21.28% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $2.18B AUM 30.3% 1-Year Est. Return
BOI
Bank of Italy Rome, Italy $2.2B AUM 1.53% 1-Year Est. Return

ADAR1 Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, ADAR1 Capital Management held 351 positions worth $1.7B, up 25% from $1.36B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

ADAR1 Capital Management deployed $308M of net new capital in Q1 2026, opening 78 new positions and adding to 102 existing holdings. Its largest new stake was Beam Therapeutics: 1,446,375 shares worth $34.5M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 89% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Fulcrum Therapeutics, an estimated $10.4M trimmed.

  • ADAR1 Capital Management's largest Q1 2026 buy was Beam Therapeutics: 1,446,375 shares worth $34.5M.
  • ADAR1 Capital Management added most to Crinetics Pharmaceuticals in Q1 2026, an estimated $37.1M increase.
  • ADAR1 Capital Management's biggest Q1 2026 reduction was Fulcrum Therapeutics, cutting an estimated $10.4M.
  • ADAR1 Capital Management fully exited Avidity Biosciences in Q1 2026, selling an estimated $39.4M.
  • ADAR1 Capital Management's ten largest holdings make up 40% of its $1.7B portfolio in Q1 2026.
  • ADAR1 Capital Management opened 78 new positions and closed 41 in Q1 2026.
  • ADAR1 Capital Management's portfolio value rose 25% quarter-over-quarter to $1.7B.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.